Because CSF tau is considered a marker of pathological processes in later stages of AD, such as neuronal death, it is possible that the levels of these markers increase in the CSF owing to inflammatory signaling in response to tissue damage. The gene discussed is MAPT; the disease is Alzheimer disease.